Prostate cancer localization with 18fluorine fluorocholine positron emission tomography |
| |
Authors: | Kwee Sandi A Coel Marc N Lim John Ko Jehoon P |
| |
Affiliation: | Hamamatsu/Queen's PET Imaging Center, Queen Emma Research Foundation, Queen's Medical Center, 1301 Punchbowl Street, Honolulu, Hawaii 96813, USA. skwee@queens.org |
| |
Abstract: | PURPOSE: We evaluated positron emission tomography (PET) with fluorine fluorocholine (F FCH) for the pretreatment localization of prostate cancer. MATERIALS AND METHODS: A total of 17 patients with prostate cancer who had not yet received treatment for the disease underwent whole body PET following intravenous administration of 3.3 to 4 MBq/kg F FCH. PET findings were compared with the results of prostate sextant biopsy and other imaging studies, and the clinical course. Tracer uptake in prostate sextants was measured as a maximum standardized uptake value (SUVmax) and evaluated as a predictor of the prostate sextant biopsy result by ROC analysis. RESULTS: Prostate sextants positive for malignancy on biopsy demonstrated significantly higher SUVmax than biopsy negative sextants (mean 5.5 vs 3.3, p <0.001). In all 6 cases in which biopsy identified malignancy on only 1 side of the prostate it was possible to identify correctly the affected side based on higher SUVmax. Area under the ROC curve for SUVmax as a discriminator of biopsy positive sextants was 0.86. In 2 patients PET demonstrated areas of abnormal uptake in the retroperitoneum. Computerized tomography confirmed the presence of retroperitoneal lymphadenopathy in these areas. In the 2 patients these lesions regressed following hormonal treatment for prostate cancer. CONCLUSIONS: Malignant tumors in the prostate gland can be localized based on a standardized regional measurement of F FCH uptake. PET with F FCH is potentially useful for staging and localizing prostate cancer. |
| |
Keywords: | prostate tomography, emission-computed prostatic neoplasms neoplasm staging |
本文献已被 ScienceDirect PubMed 等数据库收录! |